Onco Actu du 9 juillet 2019

	3.3 PRÉVENTION - VACCINS
HPV vaccine for boys raises hope of eradicating cervical cancer [The Telegraph] Professor Beate Kampmann, director of the vaccine centre at the London School of Hygiene and Tropical Medicine, said: "This decision is a triumph for gender equality in cancer prevention. "It's pleasing to see the UK follow the example of other countries like Australia, where the vaccine has been implemented for girls since 2007 and for boys since 2013."
HPV vaccine to be given to boys in effort to slash cancer rates [The Guardian] There has been a long campaign to vaccinate boys as well as girls at about the age of 12, and Scotland and Wales have already announced its introduction.
HPV vaccine for boys 'will prevent thousands of cancers' [BBC News] Boys who are 14 to 18 will not be able to get a free, catch-up vaccine in the UK - but they can buy it for around £150 per dose. Health officials say that boys are already benefitting from protection from the girls' HPV vaccination programme and this has reduced the spread of the virus.
HPV vaccine could prevent over 100,000 cancers [Public Health England] From September 2019, boys in school year 8 will be offered the free Human Papilloma Virus (HPV) vaccine for the first time.
UK offers HPV vaccines to boys, aims to stop 100,000 cancer cases [Reuters] Announcing the extension of a vaccination program to cover boys as well as girls, experts at Public Health England (PHE) said the immunization plan would prevent around 64,000 cervical cancers and nearly 50,000 non-cervical cancers by 2058.
	4.12 BIOPSIES LIQUIDES
Blood test could predict breast cancer relapse [City of Hope] Lee and his colleagues used data on 40 breast cancer patients who were followed for a median of four years. Results were validated in a separate cohort of 38 additional breast cancer patients to create a benchmark that predicts if a breast cancer patient will likely relapse within a handful of years.
	5.10 TRAITEMENTS - ESSAIS
Clinical study tests drug that may prevent cancer metastasis [VUMC] The study will test the drug ifetroban in patients who have completed cancer treatment for one of five cancer types and have no evidence of disease, but who are at very high risk for cancer recurrence.
	5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
Immunotherapy could work against bowel cancers resistant to important targeted treatment [Institute of Cancer Research] The researchers believe that cetuximab kills cancer cells in a way that sends signals that attract immune cells to the tumour – and their findings suggest that immunotherapies designed to take the brakes off the immune system could be effective in these cancers.
	5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
Cellectis Publishes New CAR Design to Control CAR T-Cells in Non-Lethal Way [Cellectis] SWIFF-CAR, a Next Generation CAR with an Embedded On/Off-Switch Increases Safety for Patients and Extends Manufacturing Possibilities.
	5.2.2 PHARMA - FUSIONS & ACQUISITIONS
Array’s colorectal cancer data shows why Pfizer splashed out $11B for the biotech [Fierce Pharma] A combination of Array’s BRAF inhibitor Braftovi, its MEK inhibitor Mektovi and the anti-EGFR drug Erbitux significantly extended lives of previously-treated patients with certain BRAF-mutant metastatic colorectal cancer (mCRC) to a median of 9 months, versus 5.4 months in those who received Erbitux and chemo. But the key question for Pfizer's future sales is whether both Array drugs are needed to reach that kind of result. Would just one do?
	5.2.3 PHARMA - ÉCONOMIE
German cancer biotech BioNTech raises a mammoth $325M in latest round, bringing total haul to $1.4B+ [EndPoints] As it stands, BioNTech’s clinical assets are all messenger RNA therapies (mRNA) — a family of treatments in which a natural system is harnessed to send the body a signal to produce its own drug — in this case, to fight cancer.
IGM Biosciences banks a $103M megaround on its quest to pioneer a new kind of cancer-fighting antibody [EndPoints] IGM Biosciences is still shying away from the limelight, only divulging in a three-paragraph statement that its lead program, a CD20xCD3 bispecific, is expected to enter the clinic later this year for relapsed/refractory B cell non-Hodgkin’s lymphoma.
	5.3 TRAITEMENTS - FDA, EMA, NICE...
Guido Rasi elected chair of International Coalition of Medicines Regulatory Authorities (ICMRA) [EMA] ICMRA brings together the leaders of regulatory authorities around the world to provide strategic directions for enhanced cooperation on common scientific, regulatory or safety challenges, improved communication and information sharing between its members and effective global crisis response mechanisms.
	5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
Karyopharm’s Xpovio nabs myeloma nod despite checkered past. But 5th line? [Fierce Pharma] Xpovio's accelerated approval marks a temporary win for Karyopharm: The drug’s final approval will depend on results from a confirmatory trial. And the company has a lot of persuading to do. The FDA went against its advisory committee's advice in granting the green light ahead of that trial, despite safety concerns.
	5.4 TRAITEMENTS - ECONOMIE
NICE shuts down AZ's Tagrisso—and backs Pfizer rival Vizimpro instead [Fierce Pharma] NICE already endorses Boehringer Ingelheim’s Gilotrif, Roche’s Tarceva and AstraZeneca’s own Iressa, it said (PDF), and while Tagrisso has topped both Tarceva and Iressa in trials, there’s no evidence that it can beat out Gilotrif.
AstraZeneca to appeal NICE rejection of Tagrisso [PMLive] NICE agreed that Tagrisso extends progression-free (PFS) and overall survival (OS) compared with first generation EGFR-targeting drugs Iressa and Tarceva, but said the size of the benefit is unclear.
	6.10.1 POLITIQUES (USA)
Trump seeks 'favored-nation' order on drug prices—but what would that even look like? [Fierce Pharma] Trump’s “favored nation” pledge on drug pricing comes as his administration touts what it has called the first year in more than half a century that net drug prices decreased from the previous 12 months. But list price hikes have continued mostly unabated in the first few months of 2019, casting doubt on Trump’s claims as he ramps up his re-election campaign for 2020.
Federal judge blocks Trump rule to require drug prices in TV ads [STAT] It’s a big loss for the Trump administration. The proposal was the first major drug pricing policy finalized by the administration since releasing its sweeping drug pricing plan in May 2018.
Executive order under construction to peg US drug prices to lowest prices abroad, Trump says [EndPoints] Essentially, instead of allowing cheaper drugs to be imported into the United States, Trump’s basic plan is to hold on to the drugs and import their prices.
Judge Blocks Trump Rule Requiring Drug Companies to List Prices in TV Ads [NY Times] "No matter how vexing the problem of spiraling drug costs may be, H.H.S. cannot do more than what Congress has authorized. The responsibility rests with Congress to act in the first instance.”
U.S. judge strikes down Trump administration rule requiring drug prices in TV ads [Reuters] Mehta in his ruling set aside the entire rule as invalid, saying the HHS lacked authority from the U.S. Congress to compel drug manufacturers to disclose list prices.
	6.11 PATIENTS
Study: Many Thyroid Cancer Patients Say They Had No Choice About Radioactive Iodine [Michigan Medicine] Better shared decision-making could help patients feel more empowered, avoid treatment side-effects and reduce overtreatment.
	6.7.1 IA/BIOINFORMATIQUE
Software Fault Leaves Patients’ Genetic Data Vulnerable to Cyber Attacks [Front Line Genomics] The weakness was identified in the widely used software programme Burrows-Wheeler Aligner (BWA). When the BWA programme imports the reference genome from government servers it is transmitted over insecure channels, leaving it vulnerable to cyber-attack.